Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
Phase 1
Terminated
- Conditions
- Advanced Solid TumorRAS MutationRAF MutationNF1 Mutation
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- ABM Therapeutics Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT05831995
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Indiana University Simon and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Advanced Solid TumorBRAF V600 Mutation
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- ABM Therapeutics Corporation
- Target Recruit Count
- 53
- Registration Number
- NCT04190628
- Locations
- 🇺🇸
University of California- San Francisco, San Francisco, California, United States
🇺🇸Stanford University School of Medicine, Stanford, California, United States
🇺🇸University of Miami Hospital Sylvester Comprehensive Cancer Center, Miami, Florida, United States
News
No news found